Search company, investor...
BioLeap company logo

BioLeap

bioleap.com

Stage

Series A | Dead

Total Raised

$5M

Last Raised

$5M

About BioLeap

BioLeap is an emerging drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap's design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap's technology provides a viable alternative to high-throughput screening and traditional shape-based "docking" approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.

Headquarters Location

7 Graphics Drive

Ewing, New Jersey, 08628,

United States

215-371-2874

Missing: BioLeap's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioLeap's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioLeap

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioLeap is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

BioLeap Patents

BioLeap has filed 7 patents.

The 3 most popular patent topics include:

  • Energy conversion
  • Air pollution control systems
  • Chemical processes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/14/2019

12/15/2020

Energy conversion, Fluid dynamics, Cooling technology, Energy conservation, Thermodynamics

Grant

Application Date

3/14/2019

Grant Date

12/15/2020

Title

Related Topics

Energy conversion, Fluid dynamics, Cooling technology, Energy conservation, Thermodynamics

Status

Grant

Latest BioLeap News

Bioleap, Inc. Supports Ethanol Industry

Feb 28, 2019

Supports Ethanol Industry Carrie Muehling Bioleap, Inc. CEO Wayne Mitchell (far left) with other members of the Bioleap team at the NEC golf tournament. The 2019 National Ethanol Conference had a new golf tournament sponsor in Bioleap, Inc. CEO Wayne Mitchell said the full-service engineering company is currently focused on reducing the carbon footprint and energy use of ethanol plants, making them more efficient and helping them to be lower cost producers. Mitchell sees a strong future for the ethanol industry. “The ethanol industry started out with kind of one vision as to where it was headed with energy security,” he said. “That’s changed with the U.S. becoming the largest exporter of energy now, but now there is a new role for ethanol in terms of octane. And that’s something that’s going to be a need and it’s going to keep this industry in business for a long time and continue to grow.”

BioLeap Frequently Asked Questions (FAQ)

  • Where is BioLeap's headquarters?

    BioLeap's headquarters is located at 7 Graphics Drive, Ewing.

  • What is BioLeap's latest funding round?

    BioLeap's latest funding round is Series A.

  • How much did BioLeap raise?

    BioLeap raised a total of $5M.

  • Who are the investors of BioLeap?

    Investors of BioLeap include Adams Capital Management and Quaker BioVentures.

  • Who are BioLeap's competitors?

    Competitors of BioLeap include Acellera.

Compare BioLeap to Competitors

P
Proteorex Therapeutics

Proteorex Therapeutics aims to discover therapeutics for diseases using a small-molecule drug discovery platform that integrates a synthesis design strategy, computational modeling, and patient-derived cell-based screening.

GNS Healthcare Logo
GNS Healthcare

GNS is a health tech company using Causal AI and simulation technology to discover and validate drug targets, simulate clinical trials. GNS’ patented AI uncovers new insights from multi-omics and real-world data to discover and prioritize biological targets, and more efficient clinical trials with patients who are likely to respond to therapies. The Gemini Digital Twin models across oncology, auto-immune diseases, and neurology enable the simulation of disease progression and drug response at the individual patient level to simulate clinical trials in diverse patient cohorts. GNS Healthcare was founded in 2000 and is based in Somerville, Massachusetts.

T
Turbine

Turbine provides a cell behavior simulation platform to understand the inner mechanisms of cancer. It identifies biomarkers of sensitivity or resistance for patient stratification in clinical trials, designs combination therapies to improve efficacy and delay resistance, and expands indication space as single or combination therapy. The company was founded in 2015 and is based in London, U.K.

O
Oncocross

Oncocross develops drugs to treat orphan diseases and intractable diseases including cancers. Using its ONCO AI platform, the company has developed products including sarcopenia drugs, anti-metastasis drugs, liver cirrhosis drugs, and irritable bowel syndrome (IBS) drugs.

My Intelligent Machines Logo
My Intelligent Machines

My Intelligent Machines is a platform as a service helping biologists analyze genomic data using AI. The platform finds the appropriate algorithms to analyze the user's data and generates text on its methods of analysis.

V
VeriSIM Life

VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM™ is a 'virtual drug development engine' that offers value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The program not only reduces the time and cost of drug discovery and development but also reduces the need for animal testing that, in the vast majority of cases, does not translate to humans. The company was founded in 2017 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.